An­oth­er ADC biotech reels in big bucks as Mark Alles’ TORL nabs $158M

Mark Alles has quick­ly put to­geth­er a megaround for his lat­est ven­ture, and it’s for the most sought-af­ter pock­et of on­col­o­gy R&D: an­ti­body-drug con­ju­gates. …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER